Lilly's Foundayo weight loss pill demonstrates heart safety and efficacy in major diabetes trial
Eli Lilly's experimental once-daily GLP-1 pill Foundayo has successfully passed a critical heart safety assessment in what stands as the largest diabetes trial conducted to date. The medication demonstrated superior blood sugar reduction compared to insulin treatments while also producing an average weight loss of 17.9 pounds among trial participants. Lilly intends to submit Foundayo for U.S. Food and Drug Administration approval specifically for diabetes treatment by the conclusion of the second quarter. This development represents a significant advancement in pharmaceutical approaches to managing diabetes and weight-related health concerns. The trial's scale and positive outcomes position Foundayo as a potentially transformative option in metabolic disorder therapeutics. The company's strategic timeline indicates regulatory filings will occur within the coming months.
Key facts
- Foundayo is a once-daily GLP-1 pill developed by Eli Lilly
- The pill passed heart safety testing in the largest diabetes trial to date
- Foundayo reduced blood sugar more effectively than insulin
- Participants lost an average of 17.9 pounds during the trial
- Lilly plans to file for FDA approval for diabetes treatment
- The FDA submission is scheduled by the end of the second quarter
- The trial focused on diabetes management outcomes
- The medication demonstrated both glycemic control and weight loss benefits
Entities
Institutions
- Eli Lilly
- U.S. Food and Drug Administration
Sources
- Quartz —